Extrapulmonary Neuroendocrine Carcinoma

subtype

Identifier: CI-CAN-00002658
Entity page: /cancer/extrapulmonary-neuroendocrine-carcinoma ↗
Edges: 408

Neighbours: 17 drugs10 trials
Drawn: 27 of 27 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Extrapulmonary Neuroendocrine Carcinoma approved for …APPROVED_FORderived10 of 10
← approved for	Retifanlimabmonoclonal antibody EMA (EU) · approved · 2024-04-19 · Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line treat…	—	approved	Merkel Cell Carcinoma	1	Regulatory	ema	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

RET Mutation SelpercatinibFDA US 2020-05-085 active / 6 trials
Curatedlevel Asensitivity· support 3civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T SelpercatinibFDA US 2020-05-085 active / 6 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET E632_L633del SelpercatinibFDA US 2020-05-085 active / 6 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T CabozantinibFDA US 2012-11-296 active / 12 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (2 approval records)context: Thyroid Gland Medullary Carcinoma
RET M918T Sorafenib0 active / 3 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerno approval record in this cancercontext: Thyroid Gland Medullary Carcinoma
RET V804M SelpercatinibFDA US 2020-05-085 active / 6 trials
Curatedlevel Csensitivity· support 2civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved for Thyroid Gland Medullary Carcinoma (5 approval records)context: Thyroid Gland Medullary Carcinoma
PIK3CA P471L Idelalisib0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for PIK3CA in this cancerno approval record in this cancercontext: Merkel Cell Carcinoma
RAD50 L1237F Checkpoint Kinase Inhibitor AZD77620 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for RAD50 in this cancerno approval record in this cancercontext: Ureter Small Cell Neuroendocrine Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Extrapulmonary Neuroendocrine Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 83show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal antibody 23 trials (13 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 17 trials (12 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Avelumabmonoclonal antibody 13 trials (5 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 12 trials (6 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 12 trials (8 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 11 trials (7 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 10 trials (8 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 9 trials (4 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Vandetanibsmall molecule 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 7 trials (2 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Extrapulmonary Neuroendocrine Carcinoma	6	Observed	clinicaltrials	graph →

Extrapulmonary Neuroendocrine Carcinoma studied in …STUDIED_INderived10 of 315show all (up to 200)
→ studied in	NCT01824875Phase 2 · completed Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 315 trials mapped (128 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 315 trials mapped (128 active)	—	—	Bladder Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06479811Phase 1 · recruiting [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers · condition mapped ONTOLOGY_EXACT · 315 trials mapped (128 active)	—	—	Sinonasal Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07472322Phase 1/Phase 2 · not yet recruiting ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 · condition mapped ONTOLOGY_EXACT · 315 trials mapped (128 active)	—	—	Merkel Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07509034Phase 1 · recruiting Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease · condition mapped ONTOLOGY_EXACT · 315 trials mapped (128 active)	—	—	Extrapulmonary Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04216732recruiting Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management · condition mapped CURATED_BROADER · 315 trials mapped (128 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05583708Phase 2 · recruiting Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer · condition mapped ONTOLOGY_EXACT · 315 trials mapped (128 active)	—	—	Merkel Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07142005recruiting Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer · condition mapped ALIAS · 315 trials mapped (128 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02293954NA · active not recruiting Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · condition mapped ONTOLOGY_EXACT · 315 trials mapped (128 active)	—	—	Thyroid Gland Medullary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ONTOLOGY_EXACT · 315 trials mapped (128 active)	—	—	Merkel Cell Carcinoma	1	Observed	clinicaltrials	graph →